Feeding and Swallowing Disorders in Children with Clefts in Orofacial Region

  • Nika Jelenc Univerzitetni rehabilitacijski Inštitut Republike Slovenije - Soča
  • Andreja Eberlinc
  • Irena Hočevar Boltežar Department of Otorhinolaryngology and Cervicofacial Surgery, University Medical Centre Ljubljana, Ljubljana, Slovenia
Keywords: orofacial clefts, feeding and swallowing problems, questionnaire, risk factors, interventions

Abstract

Background: Orofacial clefts are the most common congenital craniofacial malformations. Children with orofacial clefts do not only have problems with speech, but also with feeding and swallowing. Alternative methods of feeding need to be introduced in severe cases. Until now there has not been conducted a single study regarding feeding and swallowing problems in children with orofacial clefts in Slovenia.
Methods: The aim of the study was to determine the prevalence and the type of feeding and swallowing problems in children with orofacial clefts, aged between five months and six years. An anonymous questionnaire for parents was created, containing questions about the type of the child’s orofacial cleft, child’s possible feeding, swallowing and speech problems, and special feeding gadgets. The questionnaire was initially tested in a pilot study during routine medical follow-up visits. Afterwards, it was sent to 93 parents of children with clefs, born in a period of three consecutive years. A descriptive statistics was used to present the prevalence of feeding and swallowing problems in children with orofacial clefts. The factors correlated with feeding problems were analysed.
Results: Almost three-quarters of children had problems with feeding immediately after birth; problems with feeding later decreased, but they were still present in one quarter of all cases until the completed surgical treatment. Most difficulties occurred due to nasal regurgitation, excessive air intake while bottle feeding, and prolonged feeding time. Children with cleft palate with or without cleft lip had significantly more feeding problems in comparison to children with cleft lip only. Most parents used special feeding bottles and were generally satisfied with their use. More than a half of the parents believed that they had received too little information about feeding before and immediately after the child’s birth.
Conclusion: Despite the well-organized multidisciplinary care of children with orofacial clefts in Slovenia, parents still miss the professional counselling about feeding their children. Therefore, an additional education of nurses working in maternity hospitals will be necessary in the future. Considering the high prices of special feeding gadgets for children with orofacial clefts, covering of their costs by the health insurance would be welcome.

Downloads

Download data is not yet available.

References

Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015 Mar;136(5):E359–86. https://doi.org/10.1002/ijc.29210 PMID:25220842
Zadnik V, Primic Zakelj M, Lokar K, Jarm K, Ivanus U, Zagar T. Cancer burden in slovenia with the time trends analysis. Radiol Oncol. 2017 Feb;51(1):47–55. https://doi.org/10.1515/raon-2017-0008 PMID:28265232
Dawood S, Broglio K, Buzdar AU, Hortobagyi GN, Giordano SH. Prognosis of women with metastatic breast cancer by HER2 status and trastuzumab treatment: an institutional-based review. J Clin Oncol. 2010 Jan;28(1):92–8. https://doi.org/10.1200/JCO.2008.19.9844 PMID:19933921
Brenton JD, Carey LA, Ahmed AA, Caldas C. Molecular classification and molecular forecasting of breast cancer: ready for clinical application? J Clin Oncol. 2005 Oct;23(29):7350–60. https://doi.org/10.1200/JCO.2005.03.3845 PMID:16145060
Dai X, Cheng H, Bai Z, Li J. Breast cancer cell line classification and its relevance with breast tumor subtyping. J Cancer. 2017 Sep;8(16):3131–41. https://doi.org/10.7150/jca.18457 PMID:29158785
Cope LM, Fackler MJ, Lopez-Bujanda Z, Wolff AC, Visvanathan K, Gray JW, et al. Do breast cancer cell lines provide a relevant model of the patient tumor methylome? Rameshwar P, editor. PLoS One. 2014https://doi.org/10.1371/journal.pone.0105545.
Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. "Cope, Fackler, Lopez-Bujanda, Wolff, Visvanathan, Gray, et al., 2014")
Chavez KJ, Garimella SV, Lipkowitz S. Triple negative breast cancer cell lines: One tool in the search for better treatment of triple negative breast cancer. Eng-Wong J, Zujewski JA, editors. Breast Dis. 2010;32(1–2):35–48.
Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. "Chavez, Garimella, Lipkowitz, 2010")
Ellis IO, Collins L, Ichihara S, MacGrogan G. Invasive carcinoma of no special type. In: Lakhani SR, Elis IO, Schnitt SJ, Tan PH, Vijver MJ, editors. WHO classification of Tumours of the Breast. Lyon: IARC; 2012.
Lakhani SR, Rakha E, Simpson PT. Special subtypes. In: Lakhani SR, Elis IO, Schnitt SJ, Tan PH, Vijver MJ, editors. WHO classification of tumours of the breast. Lyon: IARC; 2012.
Perou CM, Sørlie T, Eisen MB, van de Rijn M, Jeffrey SS, Rees CA, et al. Molecular portraits of human breast tumours. Nature. 2000 Aug;406(6797):747–52. https://doi.org/10.1038/35021093 PMID:10963602
Sørlie T, Perou CM, Tibshirani R, Aas T, Geisler S, Johnsen H, et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci USA. 2001 Sep;98(19):10869–74. https://doi.org/10.1073/pnas.191367098 PMID:11553815
Sørlie T, Tibshirani R, Parker J, Hastie T, Marron JS, Nobel A, et al. Repeated observation of breast tumor subtypes in independent gene expression data sets. Proc Natl Acad Sci USA. 2003 Jul;100(14):8418–23. https://doi.org/10.1073/pnas.0932692100 PMID:12829800
Cheang MC, Chia SK, Voduc D, Gao D, Leung S, Snider J, et al. Ki67 index, HER2 status, and prognosis of patients with luminal B breast cancer. J Natl Cancer Inst. 2009 May;101(10):736–50. https://doi.org/10.1093/jnci/djp082 PMID:19436038
Smid M, Wang Y, Zhang Y, Sieuwerts AM, Yu J, Klijn JG, et al. Subtypes of breast cancer show preferential site of relapse. Cancer Res. 2008 May;68(9):3108–14. https://doi.org/10.1158/0008-5472.CAN-07-5644 PMID:18451135
Dai X, Li T, Bai Z, Yang Y, Liu X, Zhan J, et al. Breast cancer intrinsic subtype classification, clinical use and future trends. Am J Cancer Res. 2015 Sep;5(10):2929–43. PMID:26693050
Hole S, Pedersen AM, Hansen SK, Lundqvist J, Yde CW, Lykkesfeldt AE. New cell culture model for aromatase inhibitor-resistant breast cancer shows sensitivity to fulvestrant treatment and cross-resistance between letrozole and exemestane. Int J Oncol. 2015 Apr;46(4):1481–90. https://doi.org/10.3892/ijo.2015.2850 PMID:25625755
Holen I, Speirs V, Morrissey B, Blyth K. In vivo models in breast cancer research: progress, challenges and future directions. Dis Model Mech. 2017 Apr;10(4):359–71. https://doi.org/10.1242/dmm.028274 PMID:28381598
Holliday DL, Speirs V. Choosing the right cell line for breast cancer research. Breast Cancer Res. 2011 Aug;13(4):215. https://doi.org/10.1186/bcr2889 PMID:21884641
Greely HT, Cho MK. The Henrietta Lacks legacy grows. EMBO Rep. 2013 Oct;14(10):849. https://doi.org/10.1038/embor.2013.148 PMID:24030280
Lasfargues EY, Ozzello L. Cultivation of human breast carcinomas. J Natl Cancer Inst. 1958 Dec;21(6):1131–47. PMID:13611537
Amadori D, Bertoni L, Flamigni A, Savini S, De Giovanni C, Casanova S, et al. Establishment and characterization of a new cell line from primary human breast carcinoma. Breast Cancer Res Treat. 1993 Dec;28(3):251–60. https://doi.org/10.1007/BF00666586 PMID:8018954
Gazdar AF, Kurvari V, Virmani A, Gollahon L, Sakaguchi M, Westerfield M, et al. Characterization of paired tumor and non-tumor cell lines established from patients with breast cancer. Int J Cancer. 1998 Dec;78(6):766–74. https://doi.org/10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L PMID:9833771
Crossref reports the DOI should be "10.1002/(SICI)1097-0215(19981209)78:6<766::AID-IJC15>3.0.CO;2-L", not "10.1002/(SICI)1097-0215(19981209)78:6<766:AID-IJC15>3.0.CO;2-L". Edifix has used the Crossref-supplied DOI. (Ref. "Gazdar, Kurvari, Virmani, Gollahon, Sakaguchi, Westerfield, et al., 1998")
Lee AV, Oesterreich S, Davidson NE. MCF-7 cells—changing the course of breast cancer research and care for 45 years. J Natl Cancer Inst. 2015 Mar;107(7):djv073–073. https://doi.org/10.1093/jnci/djv073 PMID:25828948
International Cell Line Authentication Committee. Naming a Cell Line - ver. 1.6. [Internet]. 2015 [cited 2018 Apr 14]. p. 1. Available from: http://iclac.org/wp-content/uploads/Naming-a-Cell-Line_v1_6.pdf
Riaz M, van Jaarsveld MT, Hollestelle A, Prager-van der Smissen WJ, Heine AA, Boersma AW, et al. miRNA expression profiling of 51 human breast cancer cell lines reveals subtype and driver mutation-specific miRNAs. Breast Cancer Res. 2013 Apr;15(2):R33–33. https://doi.org/10.1186/bcr3415 PMID:23601657
Waks AG, Winer EP. Breast Cancer Treatment: A Review. JAMA. 2019 Jan;321(3):288–300. https://doi.org/10.1001/jama.2018.19323 PMID:30667505
Bertucci F, Borie N, Ginestier C, Groulet A, Charafe-Jauffret E, Adélaïde J, et al. Identification and validation of an ERBB2 gene expression signature in breast cancers. Oncogene. 2004 Apr;23(14):2564–75. https://doi.org/10.1038/sj.onc.1207361 PMID:14743203
Sahlberg KK, Hongisto V, Edgren H, Mäkelä R, Hellström K, Due EU, et al. The HER2 amplicon includes several genes required for the growth and survival of HER2 positive breast cancer cells. Mol Oncol. 2012/11/24. 2013https://doi.org/10.1016/j.molonc.2012.10.012..
Neve RM, Chin K, Fridlyand J, Yeh J, Baehner FL, Fevr T, et al. A collection of breast cancer cell lines for the study of functionally distinct cancer subtypes. Cancer Cell. 2006 Dec;10(6):515–27. https://doi.org/10.1016/j.ccr.2006.10.008 PMID:17157791
Kao J, Salari K, Bocanegra M, Choi YL, Girard L, Gandhi J, et al. Molecular profiling of breast cancer cell lines defines relevant tumor models and provides a resource for cancer gene discovery. Blagosklonny M V, editor. PLoS One. 2009https://doi.org/10.1371/journal.pone.0006146.
Edifix Bibliographic Reference Processing failed to fully style this reference. Please check the copyediting. (Ref. "Kao, Salari, Bocanegra, Choi, Girard, Gandhi, et al., 2009")
Charafe-Jauffret E, Ginestier C, Monville F, Finetti P, Adélaïde J, Cervera N, et al. Gene expression profiling of breast cell lines identifies potential new basal markers. Oncogene. 2006 Apr;25(15):2273–84. https://doi.org/10.1038/sj.onc.1209254 PMID:16288205
Lu P, Takai K, Weaver VM, Werb Z. Extracellular matrix degradation and remodeling in development and disease. Cold Spring Harb Perspect Biol. 2011 Dec;3(12):a005058. https://doi.org/10.1101/cshperspect.a005058 PMID:21917992
Dai X, Xiang L, Li T, Bai Z. Cancer hallmarks, biomarkers and breast cancer molecular subtypes. J Cancer. 2016 Jun;7(10):1281–94. https://doi.org/10.7150/jca.13141 PMID:27390604
Wang B, Elledge SJ. Ubc13/Rnf8 ubiquitin ligases control foci formation of the Rap80/Abraxas/Brca1/Brcc36 complex in response to DNA damage. Proc Natl Acad Sci USA. 2007 Dec;104(52):20759–63. https://doi.org/10.1073/pnas.0710061104 PMID:18077395
Gradisnik L, Trapecar M, Rupnik MS, Velnar T. HUIEC, Human intestinal epithelial cell line with differentiated properties: process of isolation and characterisation. Wien Klin Wochenschr. 2015 Dec;127(S5 Suppl 5):S204–9. https://doi.org/10.1007/s00508-015-0771-1 PMID:25821058
Naranda J, Gradišnik L, Gorenjak M, Vogrin M, Maver U. Isolation and characterization of human articular chondrocytes from surgical waste after total knee arthroplasty (TKA). PeerJ. 2017 Mar;5:e3079. https://doi.org/10.7717/peerj.3079 PMID:28344902
CrossMark reports an erratum (or similar issue). The CrossMark type is "isReviewOf". Additional information can be found at https://doi.org/10.7287/peerj.3079v0.1/reviews/3. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
CrossMark reports an erratum (or similar issue). The CrossMark type is "isReviewOf". Additional information can be found at https://doi.org/10.7287/peerj.3079v0.1/reviews/2. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
CrossMark reports an erratum (or similar issue). The CrossMark type is "isReviewOf". Additional information can be found at https://doi.org/10.7287/peerj.3079v0.2/reviews/3. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
CrossMark reports an erratum (or similar issue). The CrossMark type is "isReviewOf". Additional information can be found at https://doi.org/10.7287/peerj.3079v0.2/reviews/4. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
CrossMark reports an erratum (or similar issue). The CrossMark type is "isReviewOf". Additional information can be found at https://doi.org/10.7287/peerj.3079v0.1/reviews/1. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
Edifix has not found an issue number in the journal reference. Please check the volume/issue information. (Ref. "Naranda, Gradišnik, Gorenjak, Vogrin, Maver, 2017")
Lacroix M, Haibe-Kains B, Hennuy B, Laes JF, Lallemand F, Gonze I, et al. Gene regulation by phorbol 12-myristate 13-acetate in MCF-7 and MDA-MB-231, two breast cancer cell lines exhibiting highly different phenotypes. Oncol Rep. 2004 Oct;12(4):701–7. https://doi.org/10.3892/or.12.4.701 PMID:15375488
Hiscox S, Baruha B, Smith C, Bellerby R, Goddard L, Jordan N, et al. Overexpression of CD44 accompanies acquired tamoxifen resistance in MCF7 cells and augments their sensitivity to the stromal factors, heregulin and hyaluronan. BMC Cancer. 2012 Oct;12(1):458. https://doi.org/10.1186/1471-2407-12-458 PMID:23039365
Larramendy ML, Lushnikova T, Björkqvist AM, Wistuba II, Virmani AK, Shivapurkar N, et al. Comparative genomic hybridization reveals complex genetic changes in primary breast cancer tumors and their cell lines. Cancer Genet Cytogenet. 2000 Jun;119(2):132–8. https://doi.org/10.1016/S0165-4608(99)00226-5 PMID:10867149
Nestor CE, Ottaviano R, Reinhardt D, Cruickshanks HA, Mjoseng HK, McPherson RC, et al. Rapid reprogramming of epigenetic and transcriptional profiles in mammalian culture systems. Genome Biol. 2015 Feb;16(1):11. https://doi.org/10.1186/s13059-014-0576-y PMID:25648825
Widschwendter M, Jones PA. DNA methylation and breast carcinogenesis. Oncogene. 2002 Aug;21(35):5462–82. https://doi.org/10.1038/sj.onc.1205606 PMID:12154408
Kapałczyńska M, Kolenda T, Przybyła W, Zajączkowska M, Teresiak A, Filas V, et al. 2D and 3D cell cultures - a comparison of different types of cancer cell cultures. Arch Med Sci. 2016/11/18. 2018;14(4):910–9.
Hsieh C-H, Chen Y-D, Huang S-F, Wang H-M, Wu M-H. The effect of primary cancer cell culture models on the results of drug chemosensitivity assays: the application of perfusion microbioreactor system as cell culture vessel. Biomed Res Int. 2015/01/14. 2015https://doi.org/10.1155/2015/470283..
Bulysheva AA, Bowlin GL, Petrova SP, Yeudall WA. Enhanced chemoresistance of squamous carcinoma cells grown in 3D cryogenic electrospun scaffolds. Biomed Mater. 2013 Oct;8(5):055009. https://doi.org/10.1088/1748-6041/8/5/055009 PMID:24057893
Fackler MJ, Lopez Bujanda Z, Umbricht C, Teo WW, Cho S, Zhang Z, et al. Novel methylated biomarkers and a robust assay to detect circulating tumor DNA in metastatic breast cancer. Cancer Res. 2014 Apr;74(8):2160–70. https://doi.org/10.1158/0008-5472.CAN-13-3392 PMID:24737128
Christgen M, Lehmann U. MDA-MB-435: the questionable use of a melanoma cell line as a model for human breast cancer is ongoing. Cancer Biol Ther. 2007 Sep;6(9):1355–7. https://doi.org/10.4161/cbt.6.9.4624 PMID:17786032
Dvořánková B, Szabo P, Lacina L, Kodet O, Matoušková E, Smetana K Jr. Fibroblasts prepared from different types of malignant tumors stimulate expression of luminal marker keratin 8 in the EM-G3 breast cancer cell line. Histochem Cell Biol. 2012 May;137(5):679–85. https://doi.org/10.1007/s00418-012-0918-3 PMID:22270320
Hoarau-Véchot J, Rafii A, Touboul C, Pasquier J. Halfway between 2D and ANIMAL MODELS: Are 3D cultures the ideal tool to study cancer-microenvironment interactions? Int J Mol Sci. 2018 Jan;19(1):181. https://doi.org/10.3390/ijms19010181 PMID:29346265
Sotiriou C, Neo SY, McShane LM, Korn EL, Long PM, Jazaeri A, et al. Breast cancer classification and prognosis based on gene expression profiles from a population-based study. Proc Natl Acad Sci USA. 2003 Sep;100(18):10393–8. https://doi.org/10.1073/pnas.1732912100 PMID:12917485
Fan C, Oh DS, Wessels L, Weigelt B, Nuyten DS, Nobel AB, et al. Concordance among gene-expression-based predictors for breast cancer. N Engl J Med. 2006 Aug;355(6):560–9. https://doi.org/10.1056/NEJMoa052933 PMID:16899776
Lehmann BD, Bauer JA, Chen X, Sanders ME, Chakravarthy AB, Shyr Y, et al. Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies. J Clin Invest. 2011 Jul;121(7):2750–67. https://doi.org/10.1172/JCI45014 PMID:21633166
Hynds RE, Vladimirou E, Janes SM. The secret lives of cancer cell lines. Dis Model Mech. 2018 Nov;11(11):dmm037366. https://doi.org/10.1242/dmm.037366 PMID:30459183
Korch C, Spillman MA, Jackson TA, Jacobsen BM, Murphy SK, Lessey BA, et al. DNA profiling analysis of endometrial and ovarian cell lines reveals misidentification, redundancy and contamination. Gynecol Oncol. 2012/06/16. 2012https://doi.org/10.1016/j.ygyno.2012.06.017..
Gillet J-P, Varma S, Gottesman MM. The clinical relevance of cancer cell lines. J Natl Cancer Inst. 2013/02/21. 2013;105(7):452–8.
Wilding JL, Bodmer WF. Cancer cell lines for drug discovery and development. Cancer Res. 2014 May;74(9):2377–84. https://doi.org/10.1158/0008-5472.CAN-13-2971 PMID:24717177
Fusenig NE, Capes-Davis A, Bianchini F, Sundell S, Lichter P. The need for a worldwide consensus for cell line authentication: experience implementing a mandatory requirement at the International Journal of Cancer. PLoS Biol. 2017 Apr;15(4):e2001438. https://doi.org/10.1371/journal.pbio.2001438 PMID:28414712
Published
2019-10-28
How to Cite
1.
Jelenc N, Eberlinc A, Hočevar Boltežar I. Feeding and Swallowing Disorders in Children with Clefts in Orofacial Region. ZdravVestn [Internet]. 28Oct.2019 [cited 27Feb.2020];88(9-10):405-4. Available from: https://vestnik.szd.si/index.php/ZdravVest/article/view/2892
Section
Original article